Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > UK's antitrust regulator consults on merger remedies
    Finance

    UK's antitrust regulator consults on merger remedies

    Published by Global Banking & Finance Review®

    Posted on March 12, 2025

    1 min read

    Last updated: January 24, 2026

    UK's antitrust regulator consults on merger remedies - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    The UK's CMA is consulting on merger remedies, focusing on behavioural approaches to boost economic growth. Feedback is open until May 12.

    UK's Antitrust Regulator Reviews Merger Remedies Approach

    LONDON (Reuters) - Britain's competition regulator on Wednesday launched a consultation on the use of remedies to alleviate competition concerns in mergers, reflecting its new approach that aligns with the government's aim to boost economic growth.

    The Competition and Markets Authority (CMA), like other antitrust regulators, has historically preferred structural remedies, such as forcing merging companies to sell parts of their businesses, rather than behavioural remedies which could include commitments on pricing.

    The CMA said in November it would rethink its approach on remedies in order to allow more deals to go ahead, while only focusing on "truly problematic mergers".

    It said on Wednesday it was seeking views on when behavioural remedies might be appropriate, how they could preserve competition and be assessed as quickly and efficiently as possible.

    The CMA also launched a "Mergers Charter" that sets outs how it will engage with businesses and their advisers during merger reviews and what it expected from businesses in return.

    Its call for evidence in the consultation is open until May 12.

    (Reporting by Paul Sandle and Muvija M; Editing by Sachin Ravikumar)

    Key Takeaways

    • •The CMA is consulting on merger remedies to boost economic growth.
    • •Focus is shifting from structural to behavioural remedies.
    • •Consultation open until May 12 for feedback on new approaches.
    • •A new 'Mergers Charter' outlines engagement expectations.
    • •The CMA aims to streamline the review process for mergers.

    Frequently Asked Questions about UK's antitrust regulator consults on merger remedies

    1What is the main topic?

    The main topic is the UK's antitrust regulator's consultation on merger remedies to address competition concerns.

    2What are structural remedies?

    Structural remedies involve actions like forcing companies to sell parts of their businesses to maintain competition.

    3What is the 'Mergers Charter'?

    The 'Mergers Charter' outlines how the CMA will engage with businesses during merger reviews and the expectations from businesses.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    View All Finance Posts
    Previous Finance PostMoody's sees improved outlook for banks in France, Germany and elsewhere
    Next Finance PostZara owner Inditex "optimistic" about U.S. despite tariffs